Insmed (NASDAQ:INSM) Price Target Cut to $109.00 by Analysts at UBS Group

Insmed (NASDAQ:INSM) had its price objective trimmed by UBS Group from $110.00 to $109.00 in a research note published on Friday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on INSM. Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Bank of America increased their target price on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. Finally, Guggenheim restated a “buy” rating and set a $101.00 price target on shares of Insmed in a research note on Tuesday, February 25th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $93.93.

Insmed Stock Performance

Shares of INSM opened at $65.08 on Friday. The company has a market capitalization of $11.83 billion, a PE ratio of -11.64 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed has a one year low of $21.92 and a one year high of $84.91. The company’s fifty day moving average price is $72.37 and its 200 day moving average price is $73.26.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $92.82 million for the quarter, compared to analyst estimates of $91.63 million. During the same period in the prior year, the firm posted ($1.06) EPS. Insmed’s revenue for the quarter was up 22.9% on a year-over-year basis. As a group, analysts expect that Insmed will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 37,828 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total value of $2,973,659.08. Following the sale, the insider now owns 100,165 shares of the company’s stock, valued at approximately $7,873,970.65. This represents a 27.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Roger Adsett sold 42,975 shares of Insmed stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $78.61, for a total transaction of $3,378,264.75. Following the transaction, the chief operating officer now directly owns 146,082 shares of the company’s stock, valued at $11,483,506.02. This represents a 22.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 182,337 shares of company stock worth $14,284,557 over the last three months. 3.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Insmed

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after purchasing an additional 49,149 shares in the last quarter. Darwin Global Management Ltd. raised its holdings in shares of Insmed by 23.5% in the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock valued at $894,796,000 after buying an additional 2,463,261 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Insmed by 1.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,704,410 shares of the biopharmaceutical company’s stock worth $877,113,000 after buying an additional 123,429 shares in the last quarter. Capital International Investors increased its position in Insmed by 9.1% in the 4th quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock valued at $491,357,000 after acquiring an additional 593,206 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Insmed by 7.2% in the 4th quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock valued at $282,243,000 after acquiring an additional 273,759 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.